Bayer records rising pharmaceutical profits - forecast confirmed

DJ Bayer reports rising pharmaceutical profits - forecast confirmed

DOW JONES--Weak figures in Bayer's agricultural business significantly reduced its earnings at the start of the year, but the decline was not as severe as analysts expected. Adjusted Group EBITDA fell by 7.4 percent to €4.085 billion, the Leverkusen-based pharmaceutical and agrochemical company announced. The market had only expected €3.749 billion.

The improved performance was due to rising profits in the pharmaceuticals business. There, rising sales led to a 12.4 percent increase in adjusted EBITDA, while analysts had expected lower profits than in the previous year.

Bayer confirmed its currency-adjusted forecast, but expects to achieve the upper end of the forecast target corridor for both sales growth and profit margin in the pharmaceuticals sector.

After taxes and minority interests, Bayer earned 1.3 billion euros, 35.1 percent less than in the previous year. Adjusted earnings per share declined by 11.7 percent to 2.49 euros. This was primarily due to the 10.2 percent decline in EBITDA before special items in the agricultural business. Sales were only slightly below the previous year's level at 13.7 billion euros.

Analysts had forecast an average net profit of 1.45 billion euros and sales of 13.5 billion euros.

Contact the author: [email protected]

DJG/rio/mgo

(END) Dow Jones Newswires

May 13, 2025 01:56 ET (05:56 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.